Chinese society of clinical oncology (CSCO) Breast Cancer Guidelines 2022
Translational Breast Cancer Research · 2022-04 · 3 · 13-13
DOI: 10.21037/tbcr-22-21 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Translational Breast Cancer Research, 2022-04. Verfasst von Zefei Jiang und 15 weiteren Autor:innen. Beteiligte Einrichtung: The Fifth Medical Center of PLA General Hospital, Beijing, China. Die Arbeit wurde bisher 54-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Developing guidelines for the diagnosis and treatment of common cancers in China based on the evidence-based practice, the availability of diagnosis and treatment products, and the up-to-date advances in precision medicine is one of the basic tasks of the Chinese Society of Clinical Oncology (CSCO). In recent years, the availability of medical resources has become a major concern in clinical guidelines, which is particularly important for developing countries or socioeconomically diverse countries and territories. China is the world's largest developing country, with a large territory and uneven economic and academic developments. The CSCO guidelines must take into account the differences in regional development, the availability of medicines and diagnostic methods, and the social value of cancer treatment. Therefore, for each clinical problem and intervention in the CSCO guidelines, the levels of evidence should be graded according to the currently available evidences and expert consensuses, and the grades of recommendations should be based on the availability and cost-effectiveness of the products. Protocols with high evidence level and good availability are used as the Level I recommendations; protocols with relatively high evidence level but slightly lower expert consensus or with poor availability are used as the Level II recommendations; and protocols that are clinically applicable but with low evidence level are regarded as the Level III recommendations. Based on the findings of clinical research at home and abroad and the opinions of CSCO experts, the CSCO guidelines determine the levels of recommendations for clinical application. The CSCO Guidance Working Group firmly believes that evidence-based, availability-concerned, and consensus-based guidelines will be more feasible for clinical practice. Again, any comments from our readers are greatly appreciated and will be considered in updates of these guidelines, so as to maintain the accuracy, fairness, and timeliness of the CSCO guidelines.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The Fifth Medical Center of PLA General Hospital, Beijing, China.
- Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- The Fourth Affiliated Hospital of Hebei Medical University, Shijiazhuang, China.
- Guangdong Provincial Peoples Hospital, Guangzhou, China.
- The 3rd Affiliated Hospital of Kunming Medical University, Kunming, China.
- Cancer Hospital Affiliated to the University of Chinese Academy of Sciences, Hangzhou, China.
Zitieren
APA
Jiang, Z., Li, J., Chen, J., Liu, Y., Wang, K., Nie, J., Wang, X., Hao, C., Yin, Y., Wang, S., Yan, M., Wang, T., Yan, Y., Chen, X., Song, E., & CSCO BC guideline working group (2022). Chinese society of clinical oncology (CSCO) Breast Cancer Guidelines 2022. Translational Breast Cancer Research, 3, 13-13. https://doi.org/10.21037/tbcr-22-21
Vancouver
Jiang Z, Li J, Chen J, Liu Y, Wang K, Nie J, et al. Chinese society of clinical oncology (CSCO) Breast Cancer Guidelines 2022. Translational Breast Cancer Research. 2022;3:13-13. doi:10.21037/tbcr-22-21
BibTeX
@article{Jiang2022,
author = {Jiang, Zefei and Li, Jianbin and Chen, Jiayi and Liu, Yueping and Wang, Kun and Nie, Jianyun and Wang, Xiaojia and Hao, Chunfang and Yin, Yongmei and Wang, Shusen and Yan, Min and Wang, Tao and Yan, Ying and Chen, Xiaoyuan and Song, Erwei and CSCO BC guideline working group, CSCO BC guideline working group},
title = {Chinese society of clinical oncology (CSCO) Breast Cancer Guidelines 2022},
journal = {Translational Breast Cancer Research},
year = {2022},
volume = {3},
pages = {13--13},
doi = {10.21037/tbcr-22-21}
}
EUVIMED